News: Brokerage

Cahill of JLL secures 10,000 s/f for Quentis Therapeutics at the Mink Building in West Harlem

Manhattan, NY JLL completed a new transaction for Quentis Therapeutics at 1361 Amsterdam Ave., also known as the Mink Building, in the West Harlem neighborhood with Janus Property Co. The cancer immunotherapy startup firm signed a lease for 10,000 s/f of laboratory and office space.

The tenant was represented by John Cahill, senior vice president, with JLL’s Life Sciences practice group, along with Evan Margolin, vice chairman, with Savills Studley. Building owner Janus Property was represented in-house.

“Quentis will be able to expand its growing operations thanks to funds from the NYEDC,” said Cahill. “The move allows the life sciences firm to consolidate its research facilities into one state-of-the-art location in West Harlem. The location was ideal for Quentis as its new home is located near Columbia University’s Manhattanville campus and the CUNY Advanced Science Research Center.”

Quentis Therapeutics signed a lease for 10,000 square feet of research and development/ laboratory/office space and will occupy part of the fifth floor at 1361 Amsterdam Ave. The cancer immunotherapy startup is relocating to the building from the Alexandria Center for Life Sciences, 430 East 29th St., and from space it occupies at JLABS @ NYC, located at 101 Avenue of the Americas.

The biotech firm is expanding in West Harlem in part thanks to a $1 million grant from the New York Economic Development Corp. The money comes from a $10 million LifeSci NYC Expansion Space Fund established by the NYEDC to help life sciences companies expand in the city.

The five-story 1361 Amsterdam Ave., also known as the Mink Building, was constructed in 1911. The building was part of the former Yuengling Brewery complex that became a fur storage warehouse in the 1940s. The property was converted to office space after being acquired by Janus Property in 1997. The new owner has completed extensive renovations at 1361 Amsterdam Ave., with the building now featuring a new facade, new elevator, new lobby, and new windows.

READ ON THE GO
DIGITAL EDITIONS
Subscribe
Columns and Thought Leadership
A fresh start - by Shallini Mehra and Amit Doshi

A fresh start - by Shallini Mehra and Amit Doshi

For the past several years, the New York City multifamily housing market has been defined by disruption. The combined impact of the HSTPA rent laws and a sharply higher interest rate environment has fundamentally reduced
The death of the generic offering memorandum: What buyers expect in 2025 - by Kimberly Zar Bloorian

The death of the generic offering memorandum: What buyers expect in 2025 - by Kimberly Zar Bloorian

There was a time when an offering memorandum (OM) was pretty bare bones, some photos, a few bullet points on income, and a rent roll thrown in at the back. That used to get the job done. Not anymore. In 2025, buyers are sharper, faster, and more selective. They’re looking
The anticipated effect of Basel III and ISO 20022 implementation on commercial real estate - by Michael Zysman

The anticipated effect of Basel III and ISO 20022 implementation on commercial real estate - by Michael Zysman

July 1, 2025 is the deadline for US banks to begin to adopt Basel III banking standards and July 14, 2025 is the deadline for U.S. banks to adopt ISO 20022 messaging standards. Both will have a significant effect on the banking and commercial real estate (CRE) finance sectors.
Tri-state capital  migrates nationally amid  regulation pressure - by Reese Weaver

Tri-state capital migrates nationally amid regulation pressure - by Reese Weaver

New York tri-state multifamily investors are increasingly reallocating capital to less-regulated markets across the U.S. as rent control and legislative risk erode returns at home. With over 60% of New York City’s rental housing stock classified as rent-stabilized, the traditional value-add model — buying under-performing buildings,